Laura Clotet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura Clotet has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Angela Domínguez
Universitat de Barcelona
3 shared publications - Diana Toledo
Universitat de Barcelona, Barcelona, Spain
2 shared publications - Gloria Ferrús
Agència de Salut Pública Catalunya, 08005 Barcelona, Spain
2 shared publications - Ignacio Parrón
Agència de Salut Pública de Catalunya, 08005 Barcelona, Spain
2 shared publications - Irene Barrabeig
Agència de Salut Pública Catalunya, 08005 Barcelona, Spain
2 shared publications - J. M. Pina
Catalan Health Institute (ICS), Department of Health, Generalitat of Catalonia, Catalonia, Spain
2 shared publications
Latest Publications
- Open Access
Exposure Time to a Tuberculosis Index Case as a Marker of Infection in Immigrant Populations
Background: Exposure time to a tuberculosis (TB) index case may be a marker of a recent latent tuberculosis infection (LTBI) risk. The aim of this study was to determine the LTBI risk involved in immigrant contact based on exposure time to pulmonary TB index cases. Methods: We conducted a 30-month LTBI prevalence study of pulmonary TB immigrant contacts in Catalonia (1 January 2019–30 June 2021). Contacts with LTBI were identified by means of the tuberculin skin test and/or interferon gamma release assay. Variables associated with LTBI in contacts were analysed using adjusted OR (aOR) and 95% confidence interval (CI) values. Results: LTBI prevalence was 37.4% (939/2509). Prevalence was higher in men than women (40.6% versus 33.5%; p < 0.001), and in all age groups, relative to children p < 0.001)). Prevalence increased with exposure time to the index case; relative to <6 h/week exposure, LTBI risk was greater for both ≥6 h/day (aOR = 2.0; 95% CI: 1.5–2.6) and <6 h/day but ≥6 h/week (aOR = 1.6; 95% CI: 1.1–2.2). Conclusions: The LTBI risk in immigrant contacts increases with recent exposure time to the index case, and may suggest recent LTBI in immigrants.
Open AccessExposure Time to a Tuberculosis Index Case as a Marker of Infection in Immigrant Populations
Background: Exposure time to a tuberculosis (TB) index case may be a marker of a recent latent tuberculosis infection (LTBI) risk. The aim of this study was to determine the LTBI risk involved in immigrant contact based on exposure time to pulmonary TB index cases. Methods: We conducted a 30-month LTBI prevalence study of pulmonary TB immigrant contacts in Catalonia (1 January 2019–30 June 2021). Contacts with LTBI were identified by means of the tuberculin skin test and/or interferon gamma release assay. Variables associated with LTBI in contacts were analysed using adjusted OR (aOR) and 95% confidence interval (CI) values. Results: LTBI prevalence was 37.4% (939/2509). Prevalence was higher in men than women (40.6% versus 33.5%; p < 0.001), and in all age groups, relative to children p < 0.001)). Prevalence increased with exposure time to the index case; relative to <6 h/week exposure, LTBI risk was greater for both ≥6 h/day (aOR = 2.0; 95% CI: 1.5–2.6) and <6 h/day but ≥6 h/week (aOR = 1.6; 95% CI: 1.1–2.2). Conclusions: The LTBI risk in immigrant contacts increases with recent exposure time to the index case, and may suggest recent LTBI in immigrants.
- Open Access
Losses in the Care Cascade for Latent Tuberculosis Infection in the Tracing Contact Studies
Background: The control of latent tuberculosis infection (LTBI) encompasses multiple stages. The objective was to calculate the losses in the LTBI care cascade for pulmonary TB contacts in Catalonia (Spain). Methods: The LTBI care cascade was studied for pulmonary TB contacts reported from 1 January 2019 to 30 June 2021, considering three dependent variables: non-performance of testing; non-receipt of a treatment prescription; and non-adherence to treatment. Variables associated with the cascade were analysed using adjusted OR (aOR) and 95% confidence intervals (CI). Results: Identified from 847 cases of pulmonary TB were 7087 contacts, of whom 6537 (92.2%) could be screened for LTBI. LTBI prevalence was 25.5% (1670/6537); 69.4% of persons with LTBI (1159/1670) received a treatment prescription and 71.3% (827/1159) completed it. Treatment prescription was associated with age ≥65 years (aOR = 0.3; 95%CI: 0.2–0.6) and a daily exposure of ≥6 h to the TB index case (aOR = 3.6; 95%CI: 2.6–5.0). Treatment adherence was lower in men (aOR = 0.7; 95%CI: 0.5–1.0) and immigrants (aOR = 0.7; 95%CI: 0.5–0.9). Conclusions: Under 50% of contacts make it to the end of the LTBI cascade. Losses need to be reduced through education of both healthcare providers and patients and through treatment monitoring. The greater involvement of primary care physicians could help in monitoring and controling LTBI.
Open AccessLosses in the Care Cascade for Latent Tuberculosis Infection in the Tracing Contact Studies
Background: The control of latent tuberculosis infection (LTBI) encompasses multiple stages. The objective was to calculate the losses in the LTBI care cascade for pulmonary TB contacts in Catalonia (Spain). Methods: The LTBI care cascade was studied for pulmonary TB contacts reported from 1 January 2019 to 30 June 2021, considering three dependent variables: non-performance of testing; non-receipt of a treatment prescription; and non-adherence to treatment. Variables associated with the cascade were analysed using adjusted OR (aOR) and 95% confidence intervals (CI). Results: Identified from 847 cases of pulmonary TB were 7087 contacts, of whom 6537 (92.2%) could be screened for LTBI. LTBI prevalence was 25.5% (1670/6537); 69.4% of persons with LTBI (1159/1670) received a treatment prescription and 71.3% (827/1159) completed it. Treatment prescription was associated with age ≥65 years (aOR = 0.3; 95%CI: 0.2–0.6) and a daily exposure of ≥6 h to the TB index case (aOR = 3.6; 95%CI: 2.6–5.0). Treatment adherence was lower in men (aOR = 0.7; 95%CI: 0.5–1.0) and immigrants (aOR = 0.7; 95%CI: 0.5–0.9). Conclusions: Under 50% of contacts make it to the end of the LTBI cascade. Losses need to be reduced through education of both healthcare providers and patients and through treatment monitoring. The greater involvement of primary care physicians could help in monitoring and controling LTBI.
- 13 December 2012
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 32 (5) , 647-655
Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection
The purpose of this study was to evaluate the cost-effectiveness of the strategy of controlling the contacts of tuberculosis patients with latent tuberculosis infection by means of treatment with rifampin for 4 months or isoniazid for 9 months. The cost was the sum of the cost of treating latent tuberculosis infection in all contacts plus the cost of treating tuberculosis in whom the disease was not avoided. The effectiveness was expressed as cases avoided. The efficacy adopted was 90 % for rifampin for 4 months and 93 % for isoniazid for 9 months. We carried out a sensitivity analysis for efficacies of rifampin for 4 months of 80 %, 75 %, 69 % and 65 %. Of the 1,002 patients studied, 139 were treated with rifampin for 4 months and 863 were treated with isoniazid for 9 months. The cost-effectiveness was €436,842.83/50 cases avoided with rifampin for 4 months and €692,164.42/40 cases avoided with isoniazid for 9 months. Rifampin for 4 months was dominant. In the sensitivity analysis, rifampin for 4 months was dominant for efficacies of 75 % or greater. The cost-effectiveness analysis favoured the use of rifampin for 4 months when its efficacy was 75 % or greater.
- 13 December 2012
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 32 (5) , 647-655
Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection
The purpose of this study was to evaluate the cost-effectiveness of the strategy of controlling the contacts of tuberculosis patients with latent tuberculosis infection by means of treatment with rifampin for 4 months or isoniazid for 9 months. The cost was the sum of the cost of treating latent tuberculosis infection in all contacts plus the cost of treating tuberculosis in whom the disease was not avoided. The effectiveness was expressed as cases avoided. The efficacy adopted was 90 % for rifampin for 4 months and 93 % for isoniazid for 9 months. We carried out a sensitivity analysis for efficacies of rifampin for 4 months of 80 %, 75 %, 69 % and 65 %. Of the 1,002 patients studied, 139 were treated with rifampin for 4 months and 863 were treated with isoniazid for 9 months. The cost-effectiveness was €436,842.83/50 cases avoided with rifampin for 4 months and €692,164.42/40 cases avoided with isoniazid for 9 months. Rifampin for 4 months was dominant. In the sensitivity analysis, rifampin for 4 months was dominant for efficacies of 75 % or greater. The cost-effectiveness analysis favoured the use of rifampin for 4 months when its efficacy was 75 % or greater.
- 1 June 2012
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 16 (6) , 768-773
Is isoniazid for 6 months more cost-effective than isoniazid for 9 months?
SETTING: The optimal treatment for latent tuberculosis infection consists of isoniazid (H, INH) for 9–12 months. Although INH for 6 months (6H) is more cost-effective than the 12-month regimen, the cost-effectiveness of the 6H regimen and that of INH for 9 months (9H) have not been compared.OBJECTIVE: To compare the cost-effectiveness of treatment with 6H and 9H.METHODS: Cost-effectiveness was evaluated using the ratio of the cost of preventing one tuberculosis case using 6H vs. 9H. The cost was estimated as the product of the number of patients to be treated to prevent one case using 6H or 9H × the cost of 6H or 9H.RESULTS: A total of 1039 patients were studied. The number of patients that needed to be treated to prevent one case was 33 (95%CI 21–83) using 6H and 26 (95%CI 18–50) using 9H. The cost of 6H and 9H was respectively €444.34 and €578.26, and the cost ratio of preventing one case with 6H/9H was 0.98 (95%CI 0.6–1.5).CONCLUSIONS: The cost-effectiveness of treatment with 6H and 9H is similar.
- 1 June 2012
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 16 (6) , 768-773
Is isoniazid for 6 months more cost-effective than isoniazid for 9 months?
SETTING: The optimal treatment for latent tuberculosis infection consists of isoniazid (H, INH) for 9–12 months. Although INH for 6 months (6H) is more cost-effective than the 12-month regimen, the cost-effectiveness of the 6H regimen and that of INH for 9 months (9H) have not been compared.OBJECTIVE: To compare the cost-effectiveness of treatment with 6H and 9H.METHODS: Cost-effectiveness was evaluated using the ratio of the cost of preventing one tuberculosis case using 6H vs. 9H. The cost was estimated as the product of the number of patients to be treated to prevent one case using 6H or 9H × the cost of 6H or 9H.RESULTS: A total of 1039 patients were studied. The number of patients that needed to be treated to prevent one case was 33 (95%CI 21–83) using 6H and 26 (95%CI 18–50) using 9H. The cost of 6H and 9H was respectively €444.34 and €578.26, and the cost ratio of preventing one case with 6H/9H was 0.98 (95%CI 0.6–1.5).CONCLUSIONS: The cost-effectiveness of treatment with 6H and 9H is similar.